Soluble PD-L1 is a potential biomarker of cutaneous melanoma aggressiveness and metastasis in obstructive sleep apnoea patients.
Por:
Cubillos-Zapata C, Martínez-García MÁ, Campos-Rodríguez F, de la Torre MS, Nagore E, Martorell-Calatayud A, Blasco LH, Vives EC, Abad-Capa J, Montserrat JM, Cabriada-Nuño V, Cano-Pumarega I, Corral-Peñafiel J, Diaz-Cambriles T, Mediano O, Somoza-González M, Dalmau-Arias J, Almendros I, Farré R, López-Collazo E, Gozal D, García-Río F and on Behalf on the Spanish Sleep Network
Publicada:
1 feb 2019
Ahead of Print:
28 nov 2018
Resumen:
Obstructive sleep apnoea (OSA) upregulates the programmed cell death-1 receptor and its ligand (PD-L1) pathway, potentially compromising immunosurveillance. We compared circulating levels of soluble PD-L1 (sPD-L1) in patients with cutaneous melanoma according to the presence and severity of OSA, and evaluated relationships with tumour aggressiveness and invasiveness.In a multicentre observational study, 360 patients with cutaneous melanoma underwent sleep studies, and serum sPD-L1 levels were assayed using ELISA. Cutaneous melanoma aggressiveness indices included mitotic rate, Breslow index, tumour ulceration, Clark level and tumour stage, and sentinel lymph node (SLN) metastasis was recorded as a marker of invasiveness.sPD-L1 levels were higher in severe OSA compared to mild OSA or non-OSA patients. In OSA patients, sPD-L1 levels correlated with Breslow index and were higher in patients with tumour ulceration, advanced primary tumour stages or with locoregional disease. The incorporation of sPD-L1 to the classic risk factors to SLN metastasis led to net improvements in the classification of 27.3%.Thus, sPD-L1 levels are increased in melanoma patients with severe OSA, and, in addition, might serve as a potential biomarker of cutaneous melanoma aggressiveness and invasiveness in this group of subjects.
Filiaciones:
Cubillos-Zapata C:
Grupo de Enfermedades Respiratorias, Servicio de Neumología, Hospital Universitario La Paz-IdiPAZ, Madrid, Spain
Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Madrid, Spain
Martínez-García MÁ:
Respiratory Department, Hospital Universitario y Politécnico la Fe, Valencia, Spain
Campos-Rodríguez F:
Respiratory Department, Hospital Universitario de Valme, Seville, Spain
de la Torre MS:
Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Madrid, Spain
Respiratory Department, Group of Translational Research in Respiratory Medicine, Hospital Universitari Arnau de Vilanova and Santa Maria, IRBLleida, Lleida, Spain
Nagore E:
Dermatology Department, Instituto Valenciano de Oncología, Valencia, Spain
Martorell-Calatayud A:
Dermatology Department, Hospital de Manises, Valencia, Spain
:
Respiratory Department, ISABIAL, Hospital General Universitario de Alicante, Alicante, Spain
Departamento Medicina Clinica, Universidad Miguel Hernandez, Elche, Spain
Vives EC:
Respiratory Department, Hospital san Juan de Alicante, Alicante, Spain
Abad-Capa J:
Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Madrid, Spain
Respiratory Department, Hospital Germans Trias i Pujol, Centro de investigacion Biomedica, Madrid, Spain
Montserrat JM:
Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Madrid, Spain
Respiratory Department, Hospital Clinic- IDIBAPS, Barcelona, Spain
Cabriada-Nuño V:
Respiratory Department, Hospital Universitario Cruces, Bilbao, Spain
Cano-Pumarega I:
Respiratory Department, Hospital Universitario de Getafe, Madrid, Spain
Corral-Peñafiel J:
Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Madrid, Spain
Respiratory Department, Hospital Universitario S. Pedro Alcántara, Cáceres, Spain
Diaz-Cambriles T:
Respiratory Department, Hospital 12 de Octubre, Madrid, Spain
Mediano O:
Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Madrid, Spain
Respiratory Department, Hospital Universitario de Guadalajara, Guadalajara, Spain
Somoza-González M:
Pneumology Department, Hospital Consorcio Terrassa, Barcelona, Spain
Dalmau-Arias J:
Dermatology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Almendros I:
Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Madrid, Spain
Unitat de Biofísica i Bioenginyeria, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
Farré R:
Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Madrid, Spain
Unitat de Biofísica i Bioenginyeria, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona, Spain
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
López-Collazo E:
Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Madrid, Spain
TumorImmunology Laboratory IdiPAZ, Madrid, Spain
Innate Immune Response Group, IdiPAZ, Madrid, Spain
Gozal D:
Department of Child Health, University of Missouri School of Medicine, Columbia, Missouri, United States
García-Río F:
Grupo de Enfermedades Respiratorias, Servicio de Neumología, Hospital Universitario La Paz-IdiPAZ, Madrid, Spain
Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Madrid, Spain
Facultad de Medicina, Universidad Autónoma de Madrid, Madrid, Spain
Bronze
|